#Netherlands #Breast Cancer #ScreenPoint #Nijmegen #Biomediq

ScreenPoint Medical Acquires Biomediq A/S to Enhance Breast Cancer Risk Assessment

In a significant move aimed at bolstering cancer detection and patient care, ScreenPoint Medical has announced the acquisition of Biomediq A/S. This strategic partnership is set to enhance the risk assessment capabilities for breast cancer by integrating advanced imaging biomarkers into their existing platform.

For over a decade, the two companies have collaborated, sharing a common objective of improving breast cancer risk evaluation through innovative technologies. As they merge, they aim to provide healthcare professionals with optimized tools for cancer detection that leverage quantitative imaging biomarkers. The technology developed by Biomediq focuses on automated analysis of both 2D and 3D mammography, offering critical insights into future cancer risk assessments.

The Power of Combined Technologies

The combination of Biomediq's texture risk biomarker, which identifies tissue heterogeneity often associated with cancer risks, and ScreenPoint's AI algorithm, Transpara, is a promising development in breast cancer screening. A recent study published in Radiology highlighted how integrating lesion detection, volumetric density assessment, and quantitative texture analysis significantly improves breast cancer risk prediction. In fact, the outcomes suggested that women with the highest risk identified by Transpara could potentially double their chances of early cancer detection with additional imaging.

The lead author of the study, Andreas D. Lauritzen, PhD, will be joining the ScreenPoint team, bringing his expertise to accelerate the enhancements of Transpara in risk management. This acquisition not only signifies a technological upgrade but also aims to reduce unnecessary patient recalls during screenings, ultimately streamlining radiology workflows.

Bringing Cutting-edge Solutions to Radiologists

Transpara is recognized as the most clinically validated cancer screening AI available, providing radiologists with a sophisticated second opinion to help detect cancers earlier. Recently, the company released Transpara 2.1, an updated algorithm that includes features for automated density assessment (BIRADS and volumetric) along with a robust option for temporal comparison. This innovative feature allows for the analysis of ongoing studies against up to three prior examinations within a six-year period, marking a first in the industry. Both the lesion detection and density assessment capabilities of Transpara 2.1 have received CE marking and FDA approval, underscoring their reliability and compliance with international standards.

Professor Nico Karssemeijer, co-founder and scientific director of ScreenPoint Medical, expressed enthusiasm about the acquisition, stating, "Risk stratification in screening has long been advocated to enhance efficiencies for both patients and healthcare resources." He emphasized the importance of incorporating Biomediq's technology into Transpara, positioning it to offer intelligent and consistent breast cancer screening solutions for women.

Professor Mads Nielsen, co-founder of Biomediq, voiced optimism about the future, highlighting the long-standing collaboration's potential impact on patient care: "The synergy between our two technologies reflects a shared vision for streamlined radiological operations and improved patient engagement in breast cancer care." Nielsen will continue to contribute to ScreenPoint as an advisor.

With more than 35 peer-reviewed publications, Transpara stands out as the only breast cancer screening algorithm powered by AI that has been consistently evaluated in extensive screening environments, including institutions like UCLA and various prominent cancer registries. Recent findings indicated that the AI could detect up to 45% of interval cancers earlier, significantly alleviating the radiologists' workloads and optimizing their workflows.

About Biomediq

Biomediq is a dedicated research company focused on the research, development, and implementation of quantitative imaging biomarkers aimed at enhancing the screening, diagnosis, prognostication, and monitoring of breast cancer.

About ScreenPoint Medical

ScreenPoint Medical transforms cutting-edge machine-learning research into accessible technologies for radiologists, promoting efficient workflows and enhanced confidence in breast cancer risk evaluation. With a strong foundation in machine learning and imaging analytics, Transpara has earned the trust of radiologists globally. More information can be found at ScreenPoint Medical.